Quralis Closes $88 Million Series B Financing To Advance Precision Medicines For Neurodegenerative Diseases
Amount Raised
$88 Million
Round Type
Series B
CambridgeBiotechnologyHealthcareHealth CareTherapeuticsInvestors
Description
QurAlis Corporation, a clinical-stage biotechnology company developing breakthrough precision medicines for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases with genetically validated targets, today announced it has closed an oversubscribed $88 million Series B financing, bringing the total funds raised to $143.5 million. The financing was led by EQT Life Sciences, investing from the LSP Dementia Fund, Sanofi Ventures, and Droia Ventures, with participation from the ALS Investment Fund and existing investors LS Polaris Innovation Fund, Mission BioCapital, INKEF Capital, Dementia Discovery Fund, Amgen Ventures, MP Healthcare Venture Management, Mitsui Global Investment, Dolby Family Ventures, Mission Bay Capital, and Sanford Biosciences.
Quick answer
QurAlis raised $88 Million in a Series B round, dated March 9, 2023. Investors: Dolby Family Ventures, Sanford Biosciences, Mission Bay Capital, Dementia Discovery Fund, Inkef Capital, Mission Bio Capital, LS Polaris Innovation Fund and ALS Investment Fund. QurAlis is based in Cambridge, Massachusetts, United States.
- How much did QurAlis raise?
- QurAlis raised $88 Million in a Series B round on March 9, 2023.
- Who invested in QurAlis?
- Dolby Family Ventures, Sanford Biosciences, Mission Bay Capital, Dementia Discovery Fund, Inkef Capital, Mission Bio Capital, LS Polaris Innovation Fund and ALS Investment Fund are named as investors in this round.
- What does QurAlis do?
- QurAlis is a pioneering neuroscience company dedicated to developing precision medicines that target the root causes of neurodegenerative and neurological diseases.
- Where is QurAlis based and how big is it?
- QurAlis is based in Cambridge, Massachusetts, United States. Fundz records about 94 employees.
- Who are the decision-makers at QurAlis?
- Fundz holds 1 contact at QurAlis, including the Executive Officer. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Healthcare and Therapeutics around the same time
Companies in the same sectors as QurAlis that raised within 45 days of this round, from Fundz verified event records.
- Phio Pharmaceuticals raised $4M (Seed) on April 20, 2023.
- Milestone Pharmaceuticals raised $125M on March 28, 2023.
- Cognito Therapeutics raised $73M (Series B) on March 23, 2023.
- Tessera Defense & Homeland Security Inc. raised $1.5M (Seed) on February 27, 2023.
- Azora Therapeutics, Inc. (DE) raised $62K (Pre-Seed) on February 23, 2023.
- Inhibikase Therapeutics raised $4.2M (Seed) on January 27, 2023.
Who to call at QurAlis, and when
A new round usually means QurAlis is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day QurAlis raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at QurAlis, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at QurAlis. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment QurAlis raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansQurAlis raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.